{"preliminary_commentary":{"by_channel":{"x_thread":18,"youtube":4,"podcast":1,"bluesky_thread":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05578976\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"EPCORE DLBCL-2","nct_id":"NCT05578976","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=epcore-dlbcl-2-nct05578976. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"EPCORE DLBCL-2","arms":[{"description":"Participants will receive subcutaneous epcoritamab combined with intravenous rituximab, cyclophosphamide, doxorubixin hydrochloride, vincristine and oral prednisone (R-CHOP) followed by epcoritamab in 21-day cycles.","label":"Epcoritamab and R-CHOP","type":"EXPERIMENTAL"},{"description":"Participants will receive intravenous rituximab, cyclophosphamide, doxorubixin hydrochloride, vincristine and oral prednisone (R-CHOP) followed by intravenous rituximab in 21-day cycles.","label":"R-CHOP and Rituximab","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2029-12","type":"ESTIMATED"},"conditions":["Diffuse Large B-Cell Lymphoma"],"enrollment":{"count":900,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Epcoritamab","otherNames":["ABBV-GMAB-3013"],"type":"DRUG"},{"name":"Cyclophosphamide","otherNames":[],"type":"DRUG"},{"name":"Rituximab","otherNames":[],"type":"DRUG"},{"name":"Vincristine","otherNames":[],"type":"DRUG"},{"name":"Doxorubicin","otherNames":[],"type":"DRUG"},{"name":"Prednisone","otherNames":[],"type":"DRUG"}],"last_update":"2026-09-11","lead_sponsor":"Genmab","official_title":"A Phase 3, Randomized, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination With R-CHOP Compared to R-CHOP in Subjects With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2027-06","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Number of Participants with Progression-Free Survival (PFS) with an International Prognostic Index (IPI) of 3-5","timeFrame":"Up to Approximately 46 Months"}],"references":[],"start_date":{"date":"2023-02-08","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)","url":"https://clinicaltrials.gov/study/NCT05578976"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/epcore-dlbcl-2-nct05578976"}